LA JOLLA, Calif. — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today reported interim 6-week lung function results from its ongoing Phase 2a study evaluating...
Latest News
Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF)...
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July...
The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over two-thirds enrollment completed for the overall trial Results on track for...
NEW YORK, NY – GRIN Therapeutics Inc., a leader in the development of therapies to treat serious neurodevelopmental disorders, today announced initiation of the Astroscape study, the Company’s global open-label clinical trial of radiprodil, an investigational, selective and potent negative allosteric modulator of the N-methyl-D-aspartate receptor subtype 2B (NR2B or...
Brussels, Belgium – During the surgery Wednesday April 17, the Da Vinci Xi surgical system was combined with MMI’s Symani surgical system. In collaboration with abdominal surgeon Dr Martijn Schoneveld, the plastic and reconstructive surgery team performed a fully robotic lymph node transplant, overseen by Professor Moustapha Hamdi, Head of...
San Francisco, Calif. – A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder that usually kills within seven years after symptoms start. Researchers hope the trial, which will be led by UC...
LONG BEACH, Calif. — As reported in today’s issue of the journal Metabolites, researchers at Metabolomycs, a California-based biotechnology company, for the first time applied targeted mass spectrometry to show that pancreatic cancer arises through changes in cellular metabolism and that these changes can be measured with a simple blood...
Tokyo, Japan – Alternative splicing, a process where a single gene can give rise to multiple different proteins via inclusion or exclusion of certain segments of the gene sequence, is known to occur in over 90% of human genes. This leads to the production of numerous transcript isoforms (splice variants...
Tianjin, China – A transformative study has provided a profound understanding of glioblastoma’s molecular subtypes, revealing the nuances of cellular heterogeneity and the mechanisms behind resistance to treatment. This critical research not only enhances our comprehension of this aggressive cancer but also opens new frontiers for the precision-targeting of therapies,...